Vaccine Therapy in Treating Patients With Colorectal Cancer Metastatic to the Liver

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed hepatic colorectal metastases
• Must have undergone complete resection of hepatic colorectal metastases with tumor-free margins (curative resection) at least 6, but no more than 10, weeks prior to study entry
• No evaluable or measurable disease after hepatic resection, documented by intraoperative palpation or imaging studies including intraoperative ultrasound, CT scan, or MRI
• No hereditary non-polyposis colon cancer type B
• No CNS metastases
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• CTC 0-2
• Life expectancy:
• Not specified
• Hematopoietic:
• WBC at least 4,000/mm\^3
• Platelet count at least 150,000/mm\^3
• Hepatic:
• Bilirubin no greater than 2 mg/dL
• AST no greater than 2 times upper limit of normal (ULN)
• Renal:
• Creatinine no greater than 1.5 times ULN
• Gastrointestinal:
• No celiac disease
• No familial polyposis
• No Gardner's syndrome
• No Peutz-Jeghers syndrome
• Other:
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No seizure disorders requiring continuous medication
• No history of clinically significant hypersensitivity reactions, including known hypersensitivity to rodent proteins
• No other malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix or nonmelanoma skin cancer
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• No prior murine antibodies (e.g., oncoscint scan)
• No prior monoclonal antibody 3H1 anti-idiotype vaccine or monoclonal antibody 11D10 anti-idiotype vaccine
• Chemotherapy:
• No concurrent chemotherapy
• Endocrine therapy:
• No concurrent hormonal therapy except steroids for adrenal failure or hormones for non-disease-related conditions (e.g., insulin for diabetes)
• Radiotherapy:
• Not specified
• Surgery:
• See Disease Characteristics
• Other:
• Prior treatment for primary lesion or hepatic metastases allowed
• No concurrent immunomodulatory therapy